Proteoglycan metabolism during repair of the ruptured medial collateral ligament in skeletally mature rabbits.

The metabolism of the chondroitin/dermatan sulfate (CS/DS) proteoglycans (PGs) decorin and biglycan is markedly altered during short-term (3-6 weeks) and long-term (40 weeks-2 years) repair of surgically ruptured medial collateral ligaments from mature rabbits. A PG-rich extracellular matrix accumulates in injury gaps by 3 weeks postsurgery and extends into tissue regions containing the original ligaments, and elevated PG levels remain apparent up to 2 years postinjury. CS/DS PGs were prepared from such ligaments and identified after SDS-polyacrylamide gel electrophoresis by Alcian blue staining or immunoblotting. In normal ligaments, decorin is the most abundant proteoglycan (accounting for approximately 80% of the total); the remainder is biglycan and a large PG, possibly versican. In repairing ligaments, decorin is barely detected, but instead a large proteoglycan and abundant amounts of biglycan accumulate. Biglycan is present in two forms in repairing ligaments, and they can be separated on SDS-PAGE into 200- and 140-kDa forms. The slower migrating species is absent in normal ligaments and may represent a different glycoform (containing either a single or two short chondroitin/dermatan sulfate chains) of biglycan. Alteration in PG expression and posttranslational processing during medial collateral ligament repair are similar to those reported for repair and scar formation of other connective tissues. The accumulation of biglycan observed here may interfere with proper collagen network remodeling and may lead to persistent inflammatory and matrix turnover processes, thus preventing restoration of a long-term functional ligament tissue.

Glycosaminoglycan sulfation in human osteoarthritis. Disease-related alterations at the non-reducing termini of chondroitin and dermatan sulfate.

Chondroitin lyase products of aggrecan and small proteoglycans from normal and osteoarthritic cartilages were analyzed for chain internal Deltadisaccharides and terminal mono- or disaccharides. Chondroitin and dermatan sulfate chains from arthritic cartilages were of essentially normal size and internal sulfation but had significantly altered sulfation of the terminal residues. Whereas in normal cartilage, approximately 60% of terminal GalNAc4S was 4, 6-disulfated, it was reduced to approximately 30% in osteoarthritic cartilage. This is most likely due to a lower terminal GalNAc4, 6S-disulfotransferase activity and reveals that metabolic changes in osteoarthritis can affect this distinct sulfation step during chondroitin and dermatan sulfate synthesis. GlcAbeta1,3GalNAc6S-, the mimotope for antibody 3B3(-), was present on approximately 8 and approximately 10% of chains from normal and osteoarthritic cartilages, respectively. 3B3(-) assayed by immunodot blot was within the normal range for most osteoarthritic samples, with only 5 of 24 displaying elevated reactivity. This resulted not from a higher content of mimotope, but possibly from other structural changes in the proteoglycan that increase mimotope reactivity. In summary, chemical determination of sulfation isomers at the non-reducing termini of chondroitin and dermatan sulfate provides a reliable assay for monitoring proteoglycan metabolism not only during normal growth of cartilage but also during remodeling of cartilage in osteoarthritis.

Chemical and immunological assay of the nonreducing terminal residues of chondroitin sulfate from human aggrecan.

Samples of aggrecan chondroitin sulfate, isolated from normal human knee cartilages of individuals from fetal to 72 years of age, were digested with chondroitin lyases. The products were analyzed by fluorescence-based anion exchange high performance liquid chromatography to separate and quantitate nonreducing terminal structures, in addition to internal unsaturated disaccharide products. The predominant terminal structures were the monosaccharides, GalNAc4S and GalNAc4,6S as they were present on 85-90% of all chains. The remaining chains terminated with the disaccharides GlcAbeta1,3GalNAc4S and GlcAbeta1,3GalNAc6S. Marked changes in the relative abundance of these terminals were identified in the transition from growth cartilage to adult articular cartilage. First, terminal GalNAc residues were almost exclusively 4-sulfated in aggrecan from fetal through 15 years of age, but were approximately 50% 4,6-disulfated in aggrecans from adults (22-72 years of age). Second, the terminal disaccharide GlcAbeta1,3GalNAc4S was on approximately 7% of chains on aggrecan from fetal through 15 years of age, but on only approximately 3% of chains on adult aggrecan. In contrast, the proportion of chains terminating in GlcAbeta1,3GalNAc6S, approximately 9%, was unchanged from fetal to 72 years of age. This terminal disaccharide is proposed to be recognized by the widely used monoclonal antibody 3B3. However, chemical quantitation of the structure together with solid phase 3B3(-) immunoassay of fetal and adult aggrecans showed that the content of the terminal disaccharide does not necessarily correlate with immunoreactivity of the proteoglycan, as chain density and presentation on the solid phase are critical factors for recognition of chain terminals by 3B3. The quantitative results obtained from chemical analyses of all nonreducing termini of aggrecan chondroitin sulfate chains revealed important changes in chain termination that occur when cellular activities are altered as adult articular cartilage is formed after removal of growth cartilage. These findings are discussed in relation to specific enzymatic steps that generate the nonreducing termini of chains in the biosynthesis pathway of chondroitin sulfate proteoglycans and their modulation in tissue development and pathology.

Glycosaminoglycan addition to proteoglycans by articular chondrocytes--evidence for core protein-specific pathways.

The intracellular compartmentalization of enzyme activities involved in the elongation and sulfation of glycosaminoglycans on aggrecan, decorin, and fibromodulin was investigated using brefeldin A, a compound with known inhibitory action on normal vesicular transport and secretion of macromolecules. Treatment of bovine chondrocyte cultures with the compound resulted in greater than 98% inhibition of Na35SO4 incorporation into macromolecules, whereas [3H]leucine or [3H]glucosamine continued at 60-70% of the levels measured in control cultures. The release of newly synthesized products into the medium was also decreased markedly by brefeldin A to 7 and 2% of control levels for [3H]leucine- and [3H]glucosamine-labeled macromolecules, respectively. Analysis of [3H]-glucosamine-labeled products in these cultures showed that synthesis of sulfated glycosaminoglycans (chondroitin/dermatan sulfate and keratan sulfate) was inhibited in response to brefeldin A, whereas hyaluronan synthesis was essentially unaffected. Significant amounts of elongated chondroitin continued to be synthesized in the presence of brefeldin A. Immunoprecipitation of [3H]leucine-labeled decorin, aggrecan, and fibromodulin from cells showed that aggrecan and fibromodulin were not substituted with glycosamino-glycans, whereas all decorin molecules synthesized under these conditions were substituted with chondroitin. The results suggest that in articular chondrocytes, elongation of the glycosaminoglycan chains on decorin, but not their sulfation, occurs in a Golgi compartment unaffected by disruption of vesicular core protein transport. This is in contrast to glycosaminoglycan elongation and sulfation on aggrecan and fibromodulin, where both processes apparently occur in the trans-Golgi network, which becomes inaccessible to these core proteins in the presence of brefeldin A. The results further suggest that in brefeldin A-treated cells decorin is contained in a discrete ER-Golgi compartment separated from aggrecan; this compartment is accessible to p-nitrophenyl-beta-D-xylosides, since beta-xylosides become elongated with chondroitin even in the presence of brefeldin A.

Biosynthetic mechanisms for the addition of polylactosamine to chondrocyte fibromodulin.

The cartilage matrix glycoprotein fibromodulin contains four N-linked glycosylation sites which act as acceptors for the addition of sulfated polylactosamine (keratan sulfate). In the present study we examined the biosynthetic processing of these N-linked oligosaccharides for subsequent addition of polylactosamine. Chondrocytes were treated with castanospermine, 1-(+)deoxymannojirimycin, and swainsonine, radiolabeled with [3,4,5-3H]leucine, [2-3H]mannose, or [6-3H]glucosamine, and newly synthesized fibromodulin was immunoprecipitated for analysis. Castanospermine and 1-(+)deoxymannojirimycin inhibited polylactosamine addition, whereas swainsonine was not effective. This indicated that the linkage regions must be processed to GlcNAc(Man)5(GlcNAc)2Asn but do not require further modification to GlcNAc(Man)3(GlcNAc)2Asn. In both control and swainsonine-treated cells one or two N-linked oligosaccharides per molecule were modified with polylactosamine containing 4-6 repeating disaccharide units. Moreover, a single short chain was added either to the C-3 or the C-6 branch in control cultures, whereas only the C-3 branch was substituted in the presence of swainsonine. Analysis of endo-beta-galactosidase and keratanase II digestion products of the polylactosamine chains synthesized in both culture conditions showed that only about 25% of the hexosamine residues and less than 5% of the adjacent galactose residues were substituted with sulfate. These findings are discussed in relation to the regulation of fibromodulin glycosylation and the likely influence of polylactosamine structure on the extracellular interactions and turnover of fibromodulin.